[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yanyan Liu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":25,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100646121","real-world-study-of-bispecific-antibody-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-100646121",false,"NCT07695896","Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","A Real-World Study on the Efficacy and Safety of Bispecific Antibody in the Treatment of Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Age \\>= 18 years at the start of treatment\n* Histologically confirmed B-cell non-Hodgkin lymphoma\n* Relapsed or refractory disease after at least one prior line of systemic therapy\n* Planned to receive a CD20xCD3 bispecific antibody-containing regimen after study initiation\n* Signed informed consent for the investigational treatment\n\nExclusion Criteria:\n\n* Currently participating in, or planning to participate in, any interventional clinical trial\n* Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","OBSERVATIONAL","B-cell non-Hodgkin lymphoma (B-NHL) is the most common type of lymphoma. Although first-line R-CHOP can cure a proportion of patients, approximately 30%-40% relapse or become refractory (R\u002FR). CD20xCD3 bispecific antibodies, represented by glofitamab, have shown significant efficacy in clinical trials. However, large-scale real-world efficacy and safety data in Chinese clinical practice are still lacking, particularly regarding combination with different regimens and use in the relapsed population.\n\nThis is a prospective, multicenter, observational registry study evaluating the efficacy and safety of CD20xCD3 bispecific antibody-containing regimens in patients with relapsed or refractory B-cell non-Hodgkin lymphoma in a real-world setting. Efficacy is assessed using the Lugano 2014 response criteria. The primary endpoint is best objective response rate (ORR).",[24],"Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",[26,27,28,29,30,31],"B-cell non-Hodgkin lymphoma","Bispecific antibody","Glofitamab","CD20xCD3","Real-world study","Relapsed refractory","NOT_YET_RECRUITING","2026-07-06",{"date":35,"type":36},"2026-07-10","ACTUAL",{"date":38,"type":20},"2026-07",{"date":40,"type":20},"2028-12",{"name":42,"class":43},"Yanyan Liu","OTHER_GOV",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100548511","phase-1-linperlisib-combined-with-chidamide-in-patients-with-ptcl-100548511","NCT06421948","Linperlisib Combined With Chidamide in Patients With PTCL","PI3Kδ Inhibitor Linperlisib Combined With HDAC Inhibitor Chidamide Versus CHOP in Patients With Peripheral T-cell Lymphoma: a Multicenter, Open Label, Phase Ib\u002FII Study","Inclusion Criteria:\n\n* Age 18-75 years at the time of inclusion (Age 18-80 years for phase Ib and IIa study)\n* Patients with a newly diagnosed and histologically confirmed PTCL (phase Ib study includes both newly diagnosed and relapsed\u002Frefractory PTCL). Anaplastic large cell lymphoma, NK\u002FT-cell lymphoma, and primary cutaneous T-cell lymphoma are not included.\n* ECOG PS 0-2 at protocol entry\n* Estimated life expectancy of 6 months or longer\n* Measurable disease\n* Hemoglobin ≥ 8 g\u002FdL (≥5 mmol\u002Fl); Platelets ≥ 75 x 10E9\u002FL; Absolute neutrophil count ≥ 1.0 x 10E9\u002FL; Platelets ≥ 50 x 10E9\u002FL permitted if documented bone marrow involvement; Serum bilirubin ≤ 1.5 x upper limit of normal (ULN); Serum glutamic-oxaloacetic transaminase (AST) and\u002For serum glutamic-pyruvic transaminase (ALT) ≤ 2.5 x ULN, or ≤ 5 x ULN if elevation is due to hepatic involvement by lymphoma; Serum creatinine ≤ 1.5 x ULNb; left ventricular ejection fraction (LVEF) ≥ 50%\n* Women of childbearing potential must use safe anticonception (e.g. contraceptive pills, intrauterine devices etc.) during the study and 12 months after the last administration of study drugs; Male patients must use contraception for the duration of the study and 6 months after the last administration of study drugs if his partner is of childbearing potential\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients previously treated with PI3K inhibitor\n* Patients previously treated with chidamide (phase Ib study is not limited by this item)\n* Suspected or documented central nervous system involvement by lymphoma\n* Patients with positive HIV and\u002For active hepatitis B and\u002For hepatitis C infection\n* Patients with active, uncontrolled infections\n* Unwillingness or inability to comply with the protocol\n* Deemed 'unfit' by the treating physician\n* Pregnant and\u002For breastfeeding women\n* Concurrent severe and\u002For uncontrolled medical disease which is not lymphoma-related\n* Patients with contraindications to chemotherapy\n* Known hypersensitivity to one or more of the study drugs","80 Years",{"count":54,"type":20},134,"INTERVENTIONAL",[57,58],"PHASE1","PHASE2","The phase Ib part of this study aims to determine the recommended phase II dose （RP2D）of linperlisib in combination with chidamide for the treatment of peripheral T-cell lymphoma (PTCL).\n\nThe phase IIa part is designed to evaluate the preliminary efficacy and safety of the linperlisib plus chidamide regimen in newly diagnosed PTCL patients.\n\nThe phase IIb part compares the efficacy and safety of linperlisib combined with chidamide versus the standard CHOP (CHOP-like) regimen in newly diagnosed PTCL patients.",[61],"Peripheral T-cell Lymphoma","RECRUITING","2025-12-04",{"date":65,"type":36},"2025-12-05",{"date":67,"type":36},"2024-05-25",{"date":69,"type":20},"2027-12-31",{"name":42,"class":43},6,""]